Uncoupling DNA damage from chromatin damage to detoxify doxorubicin

Area of Science:

• Oncology
• Molecular Biology
• Cardiology

Background:

• Anthracyclines (doxorubicin, daunorubicin, epirubicin, idarubicin) are vital anticancer drugs.
• Their use is limited by dose-dependent cardiotoxicity, therapy-related malignancies, and infertility.
• The link between these side effects and therapeutic efficacy remains unclear.

Purpose of the Study:

• To investigate the mechanisms underlying anthracycline-induced cardiotoxicity.
• To determine if anticancer efficacy can be maintained while mitigating severe side effects.
• To develop safer anthracycline variants for improved cancer therapy.

Main Methods:

• Studied the dual cellular activities of anthracyclines: DNA damage (via topoisomerase II poisoning) and chromatin damage (histone eviction).
• Utilized mouse models and human cardiac microtissues to assess cardiotoxicity.
• Developed and tested anthracycline variants with separated cellular activities in cancer cell lines, mouse models, and leukemia patients.

Main Results:

• Anthracycline-induced cardiotoxicity requires both DNA and chromatin damage.
• Compounds with only one activity (e.g., aclarubicin, etoposide) did not cause cardiotoxicity.
• Anthracycline variants inducing chromatin damage but not DNA double-strand breaks retained anticancer potency.
• These modified anthracyclines were free of cardiotoxicity and therapy-related tumors.

Conclusions:

• Cardiotoxicity and other severe side effects of anthracyclines are separable from their anticancer efficacy.
• Anthracycline variants targeting primarily chromatin damage offer a promising strategy for safer and more effective cancer treatment.
• This approach could lead to prolonged treatment options and improved quality of life for cancer survivors.